GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » 14-Day RSI

Grifols (XMAD:GRF) 14-Day RSI : 47.48 (As of Dec. 14, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Grifols 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-14), Grifols's 14-Day RSI is 47.48.

The industry rank for Grifols's 14-Day RSI or its related term are showing as below:

XMAD:GRF's 14-Day RSI is ranked worse than
56.53% of 1095 companies
in the Drug Manufacturers industry
Industry Median: 48.1 vs XMAD:GRF: 47.48

Competitive Comparison of Grifols's 14-Day RSI

For the Drug Manufacturers - General subindustry, Grifols's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Grifols's 14-Day RSI falls into.



Grifols  (XMAD:GRF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (XMAD:GRF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Grifols 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Grifols's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.